Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis This is a multicenter, randomized, double-blind, placebo-controlled, 2-arm, parallel-group study that will investigate the efficacy and safety of mepolizumab SC in adolescent and adult subjects with moderate to severe AD. Recruiting Principal Investigator Vincent C. HoBody Locations and Systems DermatitisArea VancouverAge 18-70
Open-label Study of Dupilumab (REGN668/SAR231893) in Patients With Atopic DermatitisThis is an open label extension study for patients who participated in placebo-controlled dupilumab atopic dermatitis (AD) trials. The study primarily evaluates long term safety (adverse events) and immunogenicity.Closed for Recruitment Principal Investigator Vincent C. HoBody Locations and Systems DermatitisArea VancouverAge 18 and above
